Arnold Lippa Net Worth

Arnold Lippa biography

Dr. Arnold S. Lippa Ph.D. serves as Independent Director of the Company. Dr. Lippa has been Executive Chairman of the Board of RespireRx Pharmaceuticals Inc., since March 2013, and was appointed Chief Scientific Officer in August 2015. Previously, he served as Chief Executive Officer and President. He is also Chairman of the Board of Xintria Pharmaceutical Corporation, which he co-founded in 2006. Dr. Lippa is a Managing Member and founder of T Morgen Capital LLC, which is an investment and management company specializing in the creation and management of biomedical companies. Since 2005, T Morgen Capital has been a significant equity owner and a managing member of Aurora Capital LLC, a life science focused FINRA member firm, where Dr. Lippa represents T Morgen Capital as a Manager. In 2004, Dr. Lippa co-founded and currently is representing T Morgen Capital, a Managing Member, as a Manager of Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC, a life science fund management company and fund, respectively, both of which are affiliates of Aurora Capital. Dr. Lippa was a founder of DOV Pharmaceutical, Inc., and served as Chairman of the Board and Chief Executive Officer from its inception in April 1995 until 2005. Prior to DOV, Dr. Lippa co-founded and co-managed a number of life sciences companies, including Praxis Pharmaceuticals, Inc., which he co-founded and took public in 1985, serving as President and Chief Operating Officer from 1984 until 1987. Dr. Lippa’s experience as a biotechnology company executive and a financier qualifies him to be a director of our Company.

What is the salary of Arnold Lippa?

As the Independent Director of Hepion Pharmaceuticals Inc, the total compensation of Arnold Lippa at Hepion Pharmaceuticals Inc is $77,655. There are 7 executives at Hepion Pharmaceuticals Inc getting paid more, with Robert Foster having the highest compensation of $621,102.

How old is Arnold Lippa?

Arnold Lippa is 73, he's been the Independent Director of Hepion Pharmaceuticals Inc since 2015. There are 1 older and 9 younger executives at Hepion Pharmaceuticals Inc. The oldest executive at Hepion Pharmaceuticals Inc is Thomas Adams, 77, who is the Independent Director.

What's Arnold Lippa's mailing address?

Arnold's mailing address filed with the SEC is C/O HEPION PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON, NJ, 08837.

Insiders trading at Hepion Pharmaceuticals Inc

Over the last 5 years, insiders at Hepion Pharmaceuticals Inc have traded over $0 worth of Hepion Pharmaceuticals Inc stock and bought 119,700 units worth $247,400 . The most active insiders traders include Gary S Jacob, Peter Wijngaard, and John P Brancaccio. On average, Hepion Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of $7,481. The most recent stock trade was executed by Peter Wijngaard on 24 November 2023, trading 5,000 units of HEPA stock currently worth $15,350.

What does Hepion Pharmaceuticals Inc do?

hepion pharmaceuticals, inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the united states. it is involved in developing crv431, a cyclophilin inhibitor that has completed the phase i clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of hepatitis b. the company was formerly known as contravir pharmaceuticals, inc. and changed its name to hepion pharmaceuticals, inc. in july 2019. hepion pharmaceuticals, inc. was incorporated in 2013 and is headquartered in edison, new jersey.

Hepion Pharmaceuticals Inc executives and stock owners

Hepion Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Robert Foster,
  Chief Executive Officer, Chief Scientific Officer, Director
• Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.,
  Pres, CEO & Director
• Dr. Robert T. Foster B.Sc., BSc (Pharm), Pharm.D., Ph.D.,
  Pres, CEO & Director
• John T. Cavan,
  Chief Financial Officer
• John Cavan,
  Chief Financial Officer
• John Brancaccio,
  Independent Director
• Timothy Block,
  Independent Director
• Arnold Lippa,
  Independent Director
• Thomas Adams,
  Independent Director
• Gary Jacob,
  Chairman of the Board
• Stephen Kilmer,
  IR Contact Officer
• Peter Wijngaard,
  Independent Director
• Dr. Stephen A. Harrison,
  Member of Scientific Advisory Board & Consultant Medical Director
• Dr. John Z. Sullivan-Bolyai,
  Part-Time Consultant
• Dr. Todd M. Hobbs M.D.,
  Chief Medical Officer
• Dr. Patrick Mayo Ph.D.,
  Sr. VP of Clinical Pharmacology
• Dr. Daniel Trepanier Ph.D.,
  Sr. VP of Drug Devel.
• Sharen Pyatetskaya,
  Director of Investor Relations
• Dr. Daren Ure Ph.D.,
  Chief Scientific Officer
• Michael J. Purcell,
  Director
• Kaouthar Lbiati,
  Director